BeOne Medicines (ONC) Stock Price, News & Analysis

Company Overview

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Key Stats

• Today's Range: $280.11 to $290.67
• 50-Day Range: $240.99 to $307.23
• 52-Week Range: $170.99 to $313.29
• Volume: 423,056 shs
• Average Volume: 462,618 shs
• Market Capitalization: $31.58 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $330.89
• Consensus Rating: Buy

BeOne Medicines Stock Analysis - MarketRank™

BeOne Medicines scored higher than 26% of companies evaluated by MarketBeat, and ranked 793rd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

BeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BeOne Medicines has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BeOne Medicines are expected to grow in the coming year, from ($5.82) to $0.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BeOne Medicines is -166.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeOne Medicines is -166.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BeOne Medicines has a P/B Ratio of 8.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ONC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeOne Medicines does not currently pay a dividend.

Dividend Growth

BeOne Medicines does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ONC.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.52

News Sentiment

BeOne Medicines has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for BeOne Medicines this week, compared to 7 articles on an average week.

Search Interest

Only 4 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,294,047.00 in company stock.

Percentage Held by Insiders

Only 6.62% of the stock of BeOne Medicines is held by insiders.

Percentage Held by Institutions

48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ONC Stock Analysis - Frequently Asked Questions

How have ONC shares performed this year?

BeOne Medicines' stock was trading at $223.50 at the beginning of 2025. Since then, ONC stock has increased by 28.9% and is now trading at $288.18.

How were BeOne Medicines' earnings last quarter?

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) issued its earnings results on Wednesday, August, 6th. The company reported $0.84 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.36. The company had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.24 billion. BeOne Medicines had a negative trailing twelve-month return on equity of 1.22% and a negative net margin of 3.89%.

Who are BeOne Medicines' major shareholders?

Top institutional shareholders of BeOne Medicines include Connor Clark & Lunn Investment Management Ltd. (0.28%), Candriam S.C.A. (0.26%), M&G PLC (0.16%) and Envestnet Asset Management Inc. (0.06%). Insiders that own company stock include Lai Wang, Lai Wang, Bros Advisors Lp Baker, Xiaodong Wang, Xiaobin Wu, Titus B Ball, Aaron Rosenberg, John Oyler and Chan Henry Lee.
View institutional ownership trends.

How do I buy shares of BeOne Medicines?

Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONC
• Previous Symbol: NASDAQ:ONC
• CIK: 1651308
• Web: N/A
• Phone: 13459494123
• Fax: N/A
• Employees: 11,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BeOne Medicines: $330.89
• High Price Target: $365.00
• Low Price Target: $259.00
• Potential Upside/Downside: +14.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$644.79 million
• Net Margins: -3.89%
• Pretax Margin: -1.39%
• Return on Equity: -1.22%
• Return on Assets: -0.72%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 1.95
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: $3.81 billion
• Price / Sales: 8.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $34.40 per share
• Price / Book: 8.38

Miscellaneous

• Outstanding Shares: 109,600,000
• Free Float: 102,344,000
• Market Cap: $31.58 billion
• Optionable: N/A
• Beta: 0.27